Premium
Case report of acute encephalitis following the AstraZeneca COVID‐19 vaccine
Author(s) -
Li ShuYuan,
Chen HsinHua,
Liu PoYu,
Shi ZhiYuan,
Lin YuHui,
Tsai CheAn,
Lin ShihPing
Publication year - 2022
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.14372
Subject(s) - medicine , covid-19 , viral encephalitis , encephalitis , autoimmune encephalitis , dexamethasone , acute disseminated encephalomyelitis , pandemic , immunology , pediatrics , intensive care medicine , virology , disease , multiple sclerosis , infectious disease (medical specialty) , virus , outbreak
Coronavirus disease 2019 (COVID‐19) vaccines have proven to be safe, effective and life‐saving. However, little information is available on the neurological complications of COVID‐19 vaccine. Here, we report a case who developed acute encephalomyelitis 1 week after being vaccinated with AstraZeneca COVID‐19 vaccine (AZ vaccine). Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was also suspected. After intravenous dexamethasone and subcutaneous fondaparinux therapy, he returned to normal life without neurological sequelae. Four months later, he received Moderna COVID‐19 vaccine without any sequelae.